230 related articles for article (PubMed ID: 15671744)
1. Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers.
Mandl CW
Viral Immunol; 2004; 17(4):461-72. PubMed ID: 15671744
[TBL] [Abstract][Full Text] [Related]
2. Mimicking live flavivirus immunization with a noninfectious RNA vaccine.
Kofler RM; Aberle JH; Aberle SW; Allison SL; Heinz FX; Mandl CW
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1951-6. PubMed ID: 14769933
[TBL] [Abstract][Full Text] [Related]
3. Replication/Assembly Defective Avian Flavivirus With Internal Deletions in the Capsid Can Be Used as an Approach for Living Attenuated Vaccine.
He Y; Wang X; Guo J; Mao L; Zhang S; Hu T; Wang M; Jia R; Zhu D; Liu M; Zhao X; Yang Q; Wu Y; Zhang S; Huang J; Mao S; Ou X; Gao Q; Sun D; Liu Y; Zhang L; Yu Y; Cheng A; Chen S
Front Immunol; 2021; 12():694959. PubMed ID: 34421904
[TBL] [Abstract][Full Text] [Related]
4. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses.
Widman DG; Frolov I; Mason PW
Adv Virus Res; 2008; 72():77-126. PubMed ID: 19081489
[TBL] [Abstract][Full Text] [Related]
5. A novel principle of attenuation for the development of new generation live flavivirus vaccines.
Kofler RM; Heinz FX; Mandl CW
Arch Virol Suppl; 2004; (18):191-200. PubMed ID: 15119774
[TBL] [Abstract][Full Text] [Related]
6. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence.
Kofler RM; Heinz FX; Mandl CW
J Virol; 2002 Apr; 76(7):3534-43. PubMed ID: 11884577
[TBL] [Abstract][Full Text] [Related]
7. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
Lai CJ; Monath TP
Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
[TBL] [Abstract][Full Text] [Related]
8. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.
Aberle JH; Aberle SW; Kofler RM; Mandl CW
J Virol; 2005 Dec; 79(24):15107-13. PubMed ID: 16306582
[TBL] [Abstract][Full Text] [Related]
9. Advances in flavivirus vaccine development.
Coller BA; Clements DE; Martyak T; Yelmene M; Thorne M; Parks DE
IDrugs; 2010 Dec; 13(12):880-4. PubMed ID: 21154147
[TBL] [Abstract][Full Text] [Related]
10. Live flavivirus vaccines: reasons for caution.
Seligman SJ; Gould EA
Lancet; 2004 Jun; 363(9426):2073-5. PubMed ID: 15207960
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Internal Ribosome Entry Site/MicroRNA-Based Approach for Flavivirus Attenuation and Live Vaccine Development.
Tsetsarkin KA; Liu G; Volkova E; Pletnev AG
mBio; 2017 Apr; 8(2):. PubMed ID: 28420742
[TBL] [Abstract][Full Text] [Related]
12. Flaviviruses and flavivirus vaccines.
Heinz FX; Stiasny K
Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286
[TBL] [Abstract][Full Text] [Related]
13. Traditional and novel approaches to flavivirus vaccines.
Pugachev KV; Guirakhoo F; Trent DW; Monath TP
Int J Parasitol; 2003 May; 33(5-6):567-82. PubMed ID: 12782056
[TBL] [Abstract][Full Text] [Related]
14. Oral Vaccination with a DNA Vaccine Encoding Capsid Protein of Duck Tembusu Virus Induces Protection Immunity.
Huang J; Shen H; Jia R; Wang M; Chen S; Zhu D; Liu M; Zhao X; Yang Q; Wu Y; Liu Y; Zhang L; Yin Z; Jing B; Cheng A
Viruses; 2018 Apr; 10(4):. PubMed ID: 29642401
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-based control of tick-borne flavivirus neuropathogenesis: Challenges and perspectives.
Teterina NL; Maximova OA; Kenney H; Liu G; Pletnev AG
Antiviral Res; 2016 Mar; 127():57-67. PubMed ID: 26794396
[TBL] [Abstract][Full Text] [Related]
16. Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses.
Khou C; Pardigon N
Intervirology; 2017; 60(1-2):8-18. PubMed ID: 28869941
[TBL] [Abstract][Full Text] [Related]
17. Recent advancement in flavivirus vaccine development.
Chang GJ; Kuno G; Purdy DE; Davis BS
Expert Rev Vaccines; 2004 Apr; 3(2):199-220. PubMed ID: 15056045
[TBL] [Abstract][Full Text] [Related]
18. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.
Eckels KH; Putnak R
Adv Virus Res; 2003; 61():395-418. PubMed ID: 14714438
[TBL] [Abstract][Full Text] [Related]
19. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization.
Chávez JH; Silva JR; Amarilla AA; Moraes Figueiredo LT
Biologicals; 2010 Nov; 38(6):613-8. PubMed ID: 20817489
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the RepliVax platform for replication-defective flavivirus vaccines.
Rumyantsev AA; Giel-Moloney M; Liu Y; Gao QS; Zhang ZX; Catalan J; Frolov I; Almond J; Kleanthous H; Pugachev KV
Vaccine; 2011 Jul; 29(32):5184-94. PubMed ID: 21620917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
